A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has shown efficacy for the treatment of neurofibromatosis type 2 (NF2). Here, the authors show that VEGFRs peptide vaccination can improve hearing and reduce tumor volume in NF2 patients, including in previously bevacizumab resi...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2019-12-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-019-13640-1 |
| id |
doaj-ea9146bdc0434722af7229b82fabc004 |
|---|---|
| record_format |
Article |
| spelling |
doaj-ea9146bdc0434722af7229b82fabc0042021-05-11T11:41:50ZengNature Publishing GroupNature Communications2041-17232019-12-0110111110.1038/s41467-019-13640-1A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2Ryota Tamura0Masato Fujioka1Yukina Morimoto2Kentaro Ohara3Kenzo Kosugi4Yumiko Oishi5Mizuto Sato6Ryo Ueda7Hirokazu Fujiwara8Tetsuro Hikichi9Shinobu Noji10Naoki Oishi11Kaoru Ogawa12Yutaka Kawakami13Takayuki Ohira14Kazunari Yoshida15Masahiro Toda16Department of Neurosurgery, Keio University School of MedicineDepartment of Otorhinolaryngology, Head and Neck Surgery, Keio University School of MedicineDepartment of Neurosurgery, Keio University School of MedicineDepartment of Pathology, Keio University School of MedicineDepartment of Neurosurgery, Keio University School of MedicineDepartment of Neurosurgery, Keio University School of MedicineDepartment of Neurosurgery, Keio University School of MedicineDepartment of Neurosurgery, Keio University School of MedicineDepartment of Radiology, Keio University School of MedicineOncoTherapy Science, Inc.Division of Cellular Signaling Institute for Advanced Medical Research, Keio University School of MedicineDepartment of Otorhinolaryngology, Head and Neck Surgery, Keio University School of MedicineDepartment of Otorhinolaryngology, Head and Neck Surgery, Keio University School of MedicineDivision of Cellular Signaling Institute for Advanced Medical Research, Keio University School of MedicineDepartment of Neurosurgery, Keio University School of MedicineDepartment of Neurosurgery, Keio University School of MedicineDepartment of Neurosurgery, Keio University School of MedicineThe anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has shown efficacy for the treatment of neurofibromatosis type 2 (NF2). Here, the authors show that VEGFRs peptide vaccination can improve hearing and reduce tumor volume in NF2 patients, including in previously bevacizumab resistant tumors.https://doi.org/10.1038/s41467-019-13640-1 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Ryota Tamura Masato Fujioka Yukina Morimoto Kentaro Ohara Kenzo Kosugi Yumiko Oishi Mizuto Sato Ryo Ueda Hirokazu Fujiwara Tetsuro Hikichi Shinobu Noji Naoki Oishi Kaoru Ogawa Yutaka Kawakami Takayuki Ohira Kazunari Yoshida Masahiro Toda |
| spellingShingle |
Ryota Tamura Masato Fujioka Yukina Morimoto Kentaro Ohara Kenzo Kosugi Yumiko Oishi Mizuto Sato Ryo Ueda Hirokazu Fujiwara Tetsuro Hikichi Shinobu Noji Naoki Oishi Kaoru Ogawa Yutaka Kawakami Takayuki Ohira Kazunari Yoshida Masahiro Toda A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 Nature Communications |
| author_facet |
Ryota Tamura Masato Fujioka Yukina Morimoto Kentaro Ohara Kenzo Kosugi Yumiko Oishi Mizuto Sato Ryo Ueda Hirokazu Fujiwara Tetsuro Hikichi Shinobu Noji Naoki Oishi Kaoru Ogawa Yutaka Kawakami Takayuki Ohira Kazunari Yoshida Masahiro Toda |
| author_sort |
Ryota Tamura |
| title |
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 |
| title_short |
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 |
| title_full |
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 |
| title_fullStr |
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 |
| title_full_unstemmed |
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 |
| title_sort |
vegf receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2019-12-01 |
| description |
The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has shown efficacy for the treatment of neurofibromatosis type 2 (NF2). Here, the authors show that VEGFRs peptide vaccination can improve hearing and reduce tumor volume in NF2 patients, including in previously bevacizumab resistant tumors. |
| url |
https://doi.org/10.1038/s41467-019-13640-1 |
| work_keys_str_mv |
AT ryotatamura avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT masatofujioka avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT yukinamorimoto avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kentaroohara avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kenzokosugi avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT yumikooishi avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT mizutosato avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT ryoueda avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT hirokazufujiwara avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT tetsurohikichi avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT shinobunoji avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT naokioishi avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kaoruogawa avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT yutakakawakami avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT takayukiohira avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kazunariyoshida avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT masahirotoda avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT ryotatamura vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT masatofujioka vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT yukinamorimoto vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kentaroohara vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kenzokosugi vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT yumikooishi vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT mizutosato vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT ryoueda vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT hirokazufujiwara vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT tetsurohikichi vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT shinobunoji vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT naokioishi vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kaoruogawa vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT yutakakawakami vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT takayukiohira vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kazunariyoshida vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT masahirotoda vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 |
| _version_ |
1721446131871776768 |